Alnylam Pharmaceuticals Inc (ALNY) — Cash Flow Reinvestment Rate

Latest as of December 2025: 0.23x

Alnylam Pharmaceuticals Inc (ALNY) has a Cash Flow Reinvestment Rate of 0.23x as of December 2025, reinvesting $37.17 Million (capex $23.29 Million plus investments $-13.87 Million) from operating cash flow of $163.56 Million. Explore Alnylam Pharmaceuticals Inc capital reinvestment ratio to see what proportion of operating cash flow is directed to capital expenditures.

Reinvestment Rate

0.23x
(Capex + Investments) / Operating CF

Total Reinvested

$37.17 Million
Capex + Investments

Operating Cash Flow

$163.56 Million
USD

Capital Expenditures

$23.29 Million
USD

Alnylam Pharmaceuticals Inc Cash Flow Reinvestment Rate (2007–2025)

Historical reinvestment intensity for Alnylam Pharmaceuticals Inc across 4 annual periods. Also explore balance sheet size of Alnylam Pharmaceuticals Inc for the complete picture of this company's asset base.

Annual Cash Flow Reinvestment Rate for Alnylam Pharmaceuticals Inc (2007–2025)

Year-by-year capital reinvestment analysis for Alnylam Pharmaceuticals Inc. For live market cap and broader valuation context, see Alnylam Pharmaceuticals Inc stock valuation.

Year Reinvestment Rate Total Reinvested (USD) Operating CF Capex YoY Change
2025 1.06x $555.87 Million $524.08 Million $58.70 Million ▼ -62.9%
2023 2.86x $297.82 Million $104.16 Million $62.21 Million ▲ +1639.7%
2008 0.16x $10.76 Million $65.49 Million $10.76 Million ▲ +314.7%
2007 0.04x $7.79 Million $196.52 Million $7.79 Million
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow